Headway, the $2.3 billion mental-health platform with more than 65,000 providers, is facing organized provider opposition over two October decisions that together reshape the economics and contractual terms of practicing on its platform.
The first is a $9.99 fee for every completed appointment with a marketplace-acquired patient — continuing indefinitely.
The second is a proposed provider agreement with broad publicity rights and one-sided liability terms. CEO Andrew Adams paused the agreement the day after it was distributed. The fee remains in effect.
The recurring charge
Headway’s updated policy specifies a $9.99 deduction from each completed qualifying session.
The charge applies to patients acquired through Headway’s directory, advertising, booking staff, insurance or health-system partners, or AI integrations (the company specifically names ChatGPT). The state-by-state rollout begins November 9, with at least seven days’ notice per market.
| Question | Headway’s published answer |
| What triggers the charge? | A completed appointment with a qualifying marketplace patient |
| How long does it last? | Indefinitely, for as long as that therapist sees that patient |
| Insurance and cash pay? | Both can be subject to the fee |
| How is it collected? | Deducted from the provider’s regular payout |
| Pre-existing patients? | Exempt if the relationship predates the applicable rollout |
| Therapist-generated referrals? | Directly added patients and qualifying direct-link bookings are exempt |
| Can the therapist opt out? | Marketplace visibility can be disabled, but existing qualifying relationships remain fee-bearing |
Source: Headway marketplace service fee policy, updated October 31, 2026
The fee is not a one-time acquisition charge. A therapist seeing one qualifying patient weekly would pay Headway $519.48 over 52 completed appointments. At 40 qualifying sessions per month, the annualized cost reaches $4,795.
Headway · Marketplace service fee
One patient.
An ongoing fee.
The fee is charged on every completed appointment with a qualifying marketplace patient, for as long as you continue seeing them.
How the cost accumulates
One patient · Weekly completed visitsThe paused contract
On October 15, Headway distributed a proposed provider agreement that drew immediate opposition. Published excerpts and an independent contract review identified several provisions that departed from the company’s public 2023 agreement.
- Publicity rights described as “perpetual, worldwide, royalty-free, and irrevocable” over provider names, images, voices and supplied content
- Express permission to create derivative works and altered forms of provider material
- Express indemnification obligation shifted to the provider (the 2023 agreement contained mutual indemnification)
- A separate arbitration agreement with a 30-day opt-out window
CEO Andrew Adams paused the rollout the following day. In a reproduced email, he wrote that the agreement “was very reasonably interpreted in ways we never intended” and took responsibility. Providers who had already signed were told they would have an opportunity to review a replacement. As of November 2, no replacement agreement has been publicly identified.
Therapists raised concerns about whether the publicity language could authorize synthetic AI likenesses. No evidence reviewed establishes that Headway was building AI therapist replicas. A right written broadly enough to create concern is not proof that every conceivable use was planned.
The dependence problem
The backlash extends beyond one fee or one contract because many therapists rely on Headway for insurance credentialing, claims administration and patient referrals simultaneously. A 12-month patient non-solicitation provision — often cited as a new restriction — was already present in the 2023 agreement.
Provider accounts describe the difficulty of leaving.
- Independent credentialing with the same insurers is not always available or timely
- Existing patients depend on insurance access through the platform
- Transferring a practice to a competitor (Alma, Grow Therapy, Rula) requires rebuilding billing infrastructure
Grow Therapy’s own referral policy requires platform-generated patients to continue being managed and billed through Grow, with warnings and potential termination for violations. Platform controls over acquired patient relationships are not unique to Headway.
| Platform | Fee model | Patient-transfer restrictions |
| Headway | $9.99/session on marketplace patients (recurring) | 12-month non-solicitation for certain patients |
| Alma | $95/month (billed annually) | Membership includes insurance support and referrals |
| Grow Therapy | Platform-administered billing | Grow-sourced referrals must stay on-platform |
| Rula | Credentialing, referrals and billing bundled | Comparable transfer terms not publicly verified |
Direct fee comparison requires insurer-specific reimbursement rates and referral volumes, which are not publicly available across all platforms.
The billing angle
For behavioral health practices — one of the specialties MedHeave serves — this controversy illustrates a structural risk in platform-dependent billing. A practice that delegates credentialing, claims and patient acquisition to a single intermediary faces three vulnerabilities when terms change.
- Fee increases reduce net reimbursement without a corresponding change in payer contracts
- Contractual restrictions on patient relationships limit the ability to transition billing independently
- Credentialing dependence makes leaving the platform operationally expensive even when it is contractually permitted
Headway says its marketplace requires investment in matching, marketing, partnerships and support.
Whether a recurring per-session charge throughout a multi-year therapeutic relationship is proportionate to those costs cannot be established without patient-acquisition and retention data that have not been publicly verified.
